ASA: no clear benefit in low-risk primary prevention

In this meta-analysis of 95,000 subjects from 6 trials, ASA for primary prevention in low risk patients was associated with a small reduction in serious vascular events and coronary events (ARR of coronary events was 0.06% per year), but a higher risk of hemorrhagic stroke (absolute increase 0.01% per year) and higher risk of GI / extra-cranial bleeding (absolute increase 0.03% per year). There does not appear to be an overall advantage of ASA in low risk patients (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment